key: cord-0749765-iqayd872
authors: Matos, Thais Silva; do Nascimento, Vanessa Almeida; do Carmo, Rodrigo Feliciano; Moreno de Oliveira Fernandes, Tânia Rita; de Souza, Carlos Dornels Freire; da Silva, Tarcísio Fulgêncio Alves
title: Impact of the COVID‐19 pandemic on the diagnosis of new leprosy cases in Northeastern Brazil, 2020
date: 2021-06-22
journal: Int J Dermatol
DOI: 10.1111/ijd.15705
sha: ec1f761966faafa8853a0c455f3660cd93ff66d2
doc_id: 749765
cord_uid: iqayd872

This study analyzed the impact of the COVID‐19 pandemic on the detection of new cases of leprosy in the state of Bahia, Brazil. The periods January–September 2019 and January–September 2020 were compared. There was a 44.40% reduction in the diagnosis of leprosy when comparing the two periods (1,705 in 2019 and 948 in 2020). There was a reduction in the number of municipalities with reported cases: 251 municipalities in 2019 and 202 in 2020, expressing a reduction of 24.25%. Considering only the months following the arrival of the virus (April–September), the reduction was 51.10%. An inverse correlation was observed between the number of new cases of leprosy and the cumulative number of cases of COVID‐19 (Spearman's correlation coefficient = −0.840; P < 0.001) and the number of new monthly cases of COVID‐19 (Spearman's correlation coefficient = −0.817; P < 0.001). A slight increase was also observed in the proportion of multibacillary cases in the state (70.38% in 2019 and 72.69% in 2020) as well as in the proportion of individuals with the degree of physical disability not assessed at diagnosis, whose proportion rose from 16.39% in 2019 to 22.53% in 2020. The negative impact of COVID‐19 in tackling leprosy should be seen as a warning sign for health and political authorities.

In early December 2019, an outbreak of coronavirus disease 2019 (COVID-19), caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurred in Wuhan City, Hubei Province, China. 1 On March 11, 2020, the World Health Organization (WHO) declared the outbreak a pandemic. 2 In Brazil, the first case was confirmed in February 26. 3 The arrival of the disease in the Brazilian territory brought additional challenges, with a real burden on the public health system and potential effects in coping with other prevalent diseases in the country, among which stand out the neglected diseases such as leprosy, leishmaniasis, schistosomiasis, among others. The adoption of nonpharmacological measures to reduce contamination by COVID-19 in the population, such as social distancing and mobility restrictions, has reached specialized health services, bringing changes in the routine of these outpatient clinics (adjustments of schedules and number of attendances, removal of infected health professionals, among others). 2 On the other hand, fear has reduced the population's demand for health services for other diseases.

Among the diseases affected, leprosy stands out, a potentially disabling infectious disease when diagnosed and treated late. 6 In the global scenario, the country occupies the first posi- reduction in cases was 2.9%. Therefore, by 2020, it was expected that at least 2,020 new cases would be registered.

The social impact of the almost certain setback in coping with leprosy is another issue that deserves attention. This is due to two reasons: First, leprosy is a disease strongly associated with the living conditions of the population in a dual relationship, 8 both perpetuated by poverty and perpetuating it; second, the late diagnosis increases the risk of physical disabilities, impacting on problems such as social segregation, prejudice, and financial and psychosocial losses to the individual and their family members. 6, 7 Studies carried out in the states of Alagoas 9 and Bahia 10 point to the existence of a high hidden prevalence of the disease. High proportions of multibacillary cases and individuals with grade 2 physical disability in the diagnosis, associated with poor contact control and a cure rate still far from ideal, were challenges even before the arrival of COVID-19 in the country. 9, 10 In times of pandemic and in the post-pandemic future, these challenges will become even more serious and will require a greater commitment from the Brazilian public authorities.

Other situations make the problem even more serious: the absence of the diagnosis of children and individuals with reactive episodes, multibacillary forms, and with physical disabilities.

Although this study has not evaluated these issues, we recommend that these aspects be considered in the elaboration of strategies for coping with the disease in times of pandemic.

In addition to the challenge of maintaining disease surveillance actions, there is also a need to protect leprosy patients from possible contamination by COVID-19. 11 There are no stud- 

COVID-19): Situation Report -51. Geneva: World Health Organization

Painel Coronav ırus. Casos acumulados de COVID-19 por data de notificac ßão

Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients

Dispon ıvel em

COVID-19. Secretaria de Sa ude da Bahia/Sesab. 30 de setembro de 2020

Secretaria de Vigilância em Sa ude. Hansen ıase

Realidades do controle da hansen ıase: atualizando cen arios

Pseudo eliminac ßão da hansen ıase em estado no nordeste brasileiro: an alise a partir de regressão por pontos de inflexão e modelo bayesiano emp ırico local

Prevalência da hansen ıase, taxa de grau II de incapacidade f ısica e proporc ßão de casos multibacilares: Um paradoxo que evidencia diagn ostico tardio e prevalência oculta?

Orientac ßões para pessoas atingidas pela hansen ıase durante a pandemia COVID-19

Minist erio da Sa ude orienta a continuidade do tratamento para hansen ıase